Long-Term Tumor-Targeting Effect of E. coli as a Drug Delivery System

Gun Gyun Kim,Hongje Lee,Dan Bi Jeong,Sang Wook Kim,Jae-Seon So
DOI: https://doi.org/10.3390/ph17040421
IF: 4.6
2024-03-27
Pharmaceuticals
Abstract:To overcome the limitations of current nano/micro-scale drug delivery systems, an Escherichia coli (E. coli)-based drug delivery system could be a potential alternative, and an effective tumor-targeting delivery system can be developed by attempting to perform chemical binding to the primary amine group of a cell membrane protein. In addition, positron emission tomography (PET) is a representative non-invasive imaging technology and is actively used in the field of drug delivery along with radioisotopes capable of long-term tracking, such as zirconium-89 (89Zr). The membrane proteins were labeled with 89Zr using chelate (DFO), and not only was the long-term biodistribution in tumors and major organs evaluated in the body, but the labeling stability of 89Zr conjugated to the membrane proteins was also evaluated through continuous tracking. E. coli accumulated at high levels in the tumor within 5 min (initial time) after tail intravenous injection, and when observed after 6 days, 89Zr-DFO on the surface of E. coli was found to be stable for a long period of time in the body. In this study, we demonstrated the long-term biodistribution and tumor-targeting effect of an E. coli-based drug delivery system and verified the in vivo stability of radioisotopes labeled on the surface of E. coli.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the limitations faced by current nano/micron - level drug delivery systems in cancer treatment. Specifically, these problems include: 1. **Nonspecific distribution**: Existing drug delivery systems (such as polymer micro/nanoparticles, liposomes and magnetic nanoparticles) may be nonspecifically distributed in the blood in vivo, resulting in significant toxicity and adverse side effects. 2. **Low targeting efficiency**: The targeting efficiency of these systems is low, and it is difficult to ensure that anti - cancer tissues can obtain a sufficiently high drug concentration. To solve these problems, the author proposes a drug delivery system based on Escherichia coli (E. coli) and achieves effective tumor - targeted delivery through primary amine groups chemically bound to cell membrane proteins. In addition, the study also uses positron emission tomography (PET) technology, combined with the long - lived radioisotope zirconium - 89 (\(^{89}\)Zr), to evaluate the long - term in vivo distribution and tumor - targeting effect of E. coli. ### Main research contents 1. **Tumor - targeting ability of E. coli**: Research shows that E. coli can rapidly accumulate at the tumor site within 5 minutes after injection and remain stable after 6 days. 2. **Stability of radiolabeling**: Through continuous tracking, the long - term stability of \(^{89}\)Zr - DFO - labeled E. coli in vivo has been verified. 3. **PET imaging evaluation**: PET imaging technology was used to evaluate the long - term biodistribution of \(^{89}\)Zr - labeled E. coli in tumors and major organs. ### Research significance This study shows the potential of the E. coli - based drug delivery system in tumor - targeted therapy, especially its ability to rapidly accumulate and maintain for a long time. In addition, through PET imaging technology, the study also verified the stability of radiolabeling, providing an important basis for further developing efficient bacteria - based drug delivery systems. ### Keywords Radioactive tracer, tumor targeting, zirconium - 89, Escherichia coli, PET imaging, drug delivery Through these studies, the author hopes to develop a new delivery platform that can overcome the limitations of existing drug delivery systems, thereby improving the effectiveness of cancer treatment and reducing side effects.